SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Alonso Magdalena P)
 

Sökning: WFRF:(Alonso Magdalena P) > Increase in Epstein...

  • Jons, D.University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Göteborg, Sweden (författare)

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • Sage Publications,2022
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-102601
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-102601URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:vet swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Introduction: Epstein-Barr virus (EBV) infection may be a pre-condition  for  the development  of  multiple  sclerosis  (MS).  EBV  antibodies, predominantly anti-EBNA1, develop in the presymp-tomatic phase of virtually all MS patients. Using material from a serum repository, studies in advance of MS onset indicated that EBV  seropositivity  preceded  the  first  expression  of  incipient  axonal lesions, serum Neurofilament Light (sNFL) .Objectives: To  determine  the  onset  and  individual  order  of  appearance  of EBV  seroreactivity  and  the  serum  neuroaxonal  injury marker neurofilament light (sNfL) in a wide age spectrum of presymptomatic MS patients.Aims: To  characterize  the  presymptomatic  appearance  of  anti-bodies against an intranuclear (EBNA1) and a surface EBV anti-gen (gp350) and sNfL.Methods:  A nested  case-control  study  in  669  pre-symptomati-cally acquired blood samples from persons who later received an MS diagnosis, and from 1:1 matched control persons. Serum lev-els of EBNA1, VCA and gp350 IgG antibodies and sNFL (n=519) were   measured   in   individual   presymptomatic   samples   and   expressed  as delta  scores  with  matched  controls  in  relation  to  time until MS onset.Results: Serum levels expressed as delta scores for anti EBV and NfL IgG showed an incipient increase for anti EBNA1 and gp350 from  15-20  years  before  MS debut.  Significant  (p=0.001  and  p=0.002) from 10-15 years, with consistent delta-scores succes-sively closer to MS onset. These findings contrasted to the level of sNfL which increasingly diverged from matched controls from 5-10 years before the onset of MS. None of the individual sam-ples  negative  for  both EBNA1 and  VCA  IgG  antibodies  in  the  pre-MS group (n = 36) showed any elevation of the sNfL level.Conclusions: In  a  pre-MS  material,  the  seroreactivity  against  EBNA1  was followed  by  VCA  and  gp350,  before  increased  sNFL appeared, indicating incipient axonal injury. Together with its biological characteristics this temporal order confirms the role of EBV as a trigger of MS.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bergström, T.University of Gothenburg, Clinical Microbiology, Sahlgrenska University Hospital, Göteborg, Sweden (författare)
  • Zetterberg, H.University of Gothenburg, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Dahlgren’s Academy, Göteborg, Sweden (författare)
  • Biström, M.Umeå University, Department of Clinical Science, Neurosciences, Umeå, Sweden (författare)
  • Alonso-Magdalena, L.Skåne University Hospital, Department of Neurology, Lund, Sweden (författare)
  • Gunnarsson, Martin,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology(Swepub:oru)mign (författare)
  • Vrethem, M.Linköping University, Department of Neurology and Department of Clinical and Experimental Medicine, Linköping, Sweden (författare)
  • Blennow, K.University of Gothenburg, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Dahlgren’s Academy, Göteborg, Sweden (författare)
  • Nilsson, S.University of Gothenburg, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, Göteborg, Sweden (författare)
  • Huang, J.Karolinska Institute, Neuroimmunology Unit, The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Department of Clinical Neuroscience, Stockholm, Sweden (författare)
  • Kockum, I.Karolinska Institute, Neuroimmunology Unit, The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Department of Clinical Neuroscience, Stockholm, Sweden (författare)
  • Olsson, T.Karolinska Institute, Neuroimmunology Unit, The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Department of Clinical Neuroscience, Stockholm, Sweden (författare)
  • Waterboer, T.German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Research Program, Heidelberg, Germany (författare)
  • Sundström, P.Umeå University, Department of Clinical Science, Neurosciences, Umeå, Sweden (författare)
  • Andersen, O.University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Göteborg, Sweden (författare)
  • University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Göteborg, SwedenUniversity of Gothenburg, Clinical Microbiology, Sahlgrenska University Hospital, Göteborg, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Multiple Sclerosis Journal: Sage Publications28:Suppl. 3, s. 86-871352-45851477-0970

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy